BACKGROUND: Numerous modifiable factors have been associated with a reduced risk of colorectal cancer, including the chronic use of NSAIDs. Thus, it is biologically plausible that HMG-CoA reductase inhibitors (statins), therapeutic agents that also possess anti-inflammatory effects, are also associated with a lowered risk of colorectal cancer. OBJECTIVE: To examine the association between statin use and the risk of colorectal cancer in a large cohort of middle-aged men enrolled in a prepaid, integrated health maintenance organization. METHODS: We conducted a prospective cohort study of 69 115 Northern and Southern California Kaiser Permanente (KP) members aged 45-69 years who enrolled in the California Men's Health Study in 2002-3. Colorectal cancer cases were identified by linkage to the KP California Cancer Registries. Statin exposure, estimated from automated KP outpatient pharmacy records (available since 1991 in Southern California and 1994 in Northern California), was treated as time-varying. Cox proportional hazards regression analyses were used to estimate hazard ratios and 95% confidence intervals (CIs), while controlling for potential confounders. RESULTS: During a maximum of 3.5 years of follow-up, 171 colorectal cancer cases were identified. Compared with nonuse, the adjusted hazard ratio for ever use of statins was 0.89 (95% CI 0.61, 1.30). The hazard ratio for statin use of >or=5 years was 0.83 (95% CI 0.43, 1.63). The results did not differ markedly by type or severity of disease. There was also no evidence of effect modification by regular NSAID use. However, the stratified analyses were limited by small numbers. CONCLUSION: These findings provide little support for an association between the use of statins and the risk of colorectal cancer in men. There was some suggestion of a modest inverse association between statin use for >or=5 years and risk of colorectal cancer; however, the possibility that this observation may be related to regular NSAID use cannot be ruled out.
BACKGROUND: Numerous modifiable factors have been associated with a reduced risk of colorectal cancer, including the chronic use of NSAIDs. Thus, it is biologically plausible that HMG-CoA reductase inhibitors (statins), therapeutic agents that also possess anti-inflammatory effects, are also associated with a lowered risk of colorectal cancer. OBJECTIVE: To examine the association between statin use and the risk of colorectal cancer in a large cohort of middle-aged men enrolled in a prepaid, integrated health maintenance organization. METHODS: We conducted a prospective cohort study of 69 115 Northern and Southern California Kaiser Permanente (KP) members aged 45-69 years who enrolled in the California Men's Health Study in 2002-3. Colorectal cancer cases were identified by linkage to the KP California Cancer Registries. Statin exposure, estimated from automated KP outpatient pharmacy records (available since 1991 in Southern California and 1994 in Northern California), was treated as time-varying. Cox proportional hazards regression analyses were used to estimate hazard ratios and 95% confidence intervals (CIs), while controlling for potential confounders. RESULTS: During a maximum of 3.5 years of follow-up, 171 colorectal cancer cases were identified. Compared with nonuse, the adjusted hazard ratio for ever use of statins was 0.89 (95% CI 0.61, 1.30). The hazard ratio for statin use of >or=5 years was 0.83 (95% CI 0.43, 1.63). The results did not differ markedly by type or severity of disease. There was also no evidence of effect modification by regular NSAID use. However, the stratified analyses were limited by small numbers. CONCLUSION: These findings provide little support for an association between the use of statins and the risk of colorectal cancer in men. There was some suggestion of a modest inverse association between statin use for >or=5 years and risk of colorectal cancer; however, the possibility that this observation may be related to regular NSAID use cannot be ruled out.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Eric J Jacobs; Carmen Rodriguez; Kerri A Brady; Cari J Connell; Michael J Thun; Eugenia E Calle Journal: J Natl Cancer Inst Date: 2006-01-04 Impact factor: 13.506
Authors: J R Downs; M Clearfield; H A Tyroler; E J Whitney; W Kruyer; A Langendorfer; V Zagrebelsky; S Weis; D R Shapiro; P A Beere; A M Gotto Journal: Am J Cardiol Date: 2001-05-01 Impact factor: 2.778
Authors: F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: Denise M Boudreau; Elizabeth Koehler; Stephen J Rulyak; Sebastien Haneuse; Robert Harrison; Margaret T Mandelson Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10-28 Impact factor: 4.254
Authors: Timo E Strandberg; Kalevi Pyörälä; Thomas J Cook; Lars Wilhelmsen; Ole Faergeman; Gudmundur Thorgeirsson; Terje R Pedersen; John Kjekshus Journal: Lancet Date: 2004 Aug 28-Sep 3 Impact factor: 79.321
Authors: Wojciech Feleszko; Ahmad Jalili; Dominika Olszewska; Izabela Mlynarczuk; Tomasz Grzela; Adam Giermasz; Marek Jakóbisiak Journal: Oncol Rep Date: 2002 Jul-Aug Impact factor: 3.906
Authors: Shelley M Enger; Stephen K Van den Eeden; Barbara Sternfeld; Ronald K Loo; Charles P Quesenberry; Sarah Rowell; Marianne C Sadler; Donna M Schaffer; Laurel A Habel; Bette J Caan Journal: BMC Public Health Date: 2006-06-30 Impact factor: 3.295
Authors: Michael S Simon; Carol A Rosenberg; Rebecca J Rodabough; Phillip Greenland; Ira Ockene; Hemant K Roy; Dorothy S Lane; Jane A Cauley; Janardan Khandekar Journal: Ann Epidemiol Date: 2011-11-04 Impact factor: 3.797
Authors: Jung Eun Lee; Yoshifumi Baba; Kimmie Ng; Edward Giovannucci; Charles S Fuchs; Shuji Ogino; Andrew T Chan Journal: Cancer Prev Res (Phila) Date: 2011-06-16
Authors: Kimmie Ng; Shuji Ogino; Jeffrey A Meyerhardt; Jennifer A Chan; Andrew T Chan; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Al B Benson; Paul L Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Monica M Bertagnolli; Alan P Venook; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2011-08-17 Impact factor: 13.506